|
UK health cost body backs Novartis asthma drug in fresh U-turn
Reuters LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … NICE U-turn over asthma drug omalizumab |
View full post on asthma – Google News